Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Innovation in anti Human Immunodeficiency Virus
share announcement

Innovation in anti Human Immunodeficiency Virus

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "HIV Vaccines".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 1945

Special Issue Editor

Dr. Khan Nabab

E-Mail Website
Guest Editor
Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58203, USA
Interests: HIV-1; HIV-1 associated neurocognitive disorders; neurovirology; Alzheimer disease; endolysosomes and autophagy; innate immunity; coronaviruses

Special Issue Information

Dear Colleagues,

Human immunodeficiency virus is a virus that causes a deficiency of the human immune system. HIV destroys the body's T lymphocytes, thus blocking cellular and humoral immunity processes, resulting in immune system paralysis, which leads to the spread of various diseases in the body, and eventually AIDS. Due to the extremely rapid mutation of HIV, it is difficult to produce a specific vaccine, so far there is no effective treatment, posing a great threat to human health.

There is therefore an urgent need for further research into HIV's function to help researchers develop new treatments that can effectively fight the disease. In this regard, we have launched this Vaccine Special Issue (MDPI), and we welcome your valuable contributions in the form of an influential article focusing on the theme "Innovation in anti Human Immunodeficiency Virus".

We encourage and welcome submissions of manuscripts regarding the following topics:

  1. Perspectives and reviews regarding the human immunodeficiency virus;
  2. Original or review articles regarding human immunodeficiency virus: analysis and detection;
  3. Case reports or case series of AIDS with typical or atypical presentation;
  4. Developing and improving new technologies or vaccines for use against immunodeficiency-based viruses.

Dr. Khan Nabab
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immune
  • HIV
  • diseases
  • vaccine
  • virus

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2995 KiB  
Article
Divergent Cytokine and Chemokine Responses at Early Acute Simian Immunodeficiency Virus Infection Correlated with Virus Replication and CD4 T Cell Loss in a Rhesus Macaque Model
by Nongthombam Boby, Apurv Srivastav, Sudesh K. Srivastav and Bapi Pahar
Vaccines 2023, 11(2), 264; https://doi.org/10.3390/vaccines11020264 - 25 Jan 2023
Cited by 2 | Viewed by 1621
Abstract
Cytokine and chemokine levels remain one of the significant predictive factors of HIV pathogenesis and disease outcome. Understanding the impact of cytokines and chemokines during early acute infection will help to recognize critical changes during HIV pathogenesis and might assist in establishing improved [...] Read more.
Cytokine and chemokine levels remain one of the significant predictive factors of HIV pathogenesis and disease outcome. Understanding the impact of cytokines and chemokines during early acute infection will help to recognize critical changes during HIV pathogenesis and might assist in establishing improved HIV treatment and prevention methods. Sixty-one cytokines and chemokines were evaluated in the plasma of an SIV-infected rhesus macaque model. A substantial change in 11 cytokines/growth factors and 9 chemokines were observed during acute infection. Almost all the cytokines/chemokines were below the baseline values for an initial couple of days of infection. We detected six important cytokines/chemokines, such as IL-18, IP-10, FLT3L, MCP-1, MCP-2, and MIP-3β, that can be used as biomarkers to predict the peripheral CD4+ T cell loss and increased viral replication during the acute SIV/HIV infection. Hence, regulating IL-18, IP-10, FLT3L, MCP-1, MCP-2, and MIP-3β expression might provide an antiviral response to combat acute SIV/HIV infection. Full article
(This article belongs to the Special Issue Innovation in anti Human Immunodeficiency Virus)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop